Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1849-1856

  Liu, Hui ^a   Zhang, Tiantuo ^a   Ye, Jin ^a   Li, Hongtao ^a   Huang, Jing ^a   Li, Xiaodong ^b   Wu, Benquan ^a   Huang, Xubing ^a   Hou, Jinghui ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Chemotherapy; Cytotoxic T lymphocytes; Immunity; Non small cell lung cancer; Prognostic factor; Tumor infiltrating lymphocytes

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CD3+ TUMOR ASSOCIATED LEUKOCYTE; CD4+ TUMOR ASSOCIATED LEUKOCYTE; CD8+ TUMOR ASSOCIATED LEUKOCYTE; CELL DENSITY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOXP3+ TUMOR ASSOCIATED LEUKOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84867583274     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1231-7     Document Type: Article

References (30)

1. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565-1570
2. Pages F, Galon J, Dieu-Nosjean MC et al (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29:1093-1102
3. Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151-160
4. Liu H, Zhang T, Li X et al (2008) Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci 99:2185-2192
5. Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964
6. Fridman WH, Galon J, Pagés F et al (2011) Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71:5601-5605
7. Tosolini M, Kirilovsky A, Mlecnik B et al (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71:1263-1271
8. Sato E, Olson SH, Ahn J et al (2005) Intraepithelial CD8? tumorinfiltrating lymphocytes and a high CD8?/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci 102:18538-18543
9. Sheu BC, Chang WC, Lin HH et al (2007) Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia. J Obstet Gynaecol Res 33:103-113
10. Liu F, Lang R, Zhao J et al (2011) CD8? cytotoxic T cell and FOXP3? regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 130:645-655
11. Al-Shibli KI, Donnem T, Al-Saad S et al (2008) Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 14:5220-5227
12. Hiraoka K, Miyamoto M, Cho Y et al (2006) Concurrent infiltration by CD8? T cells and CD4? T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 94:275-280
13. Ladoire S, Martin F, Ghiringhelli F (2011) Prognostic role of FOXP3? regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 60:909-918
14. Piersma SJ, Welters MJ, van der Burg SH (2008) Tumor-specific regulatory T cells in cancer patients. Hum Immunol 69:241-249
15. Elkord E, Alcantar-Orozco EM, Dovedi SJ et al (2010) T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 10:1573-1586
16. Petersen RP, Campa MJ, Sperlazza J et al (2006) Tumor infiltrating Foxp3? regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 107:2866-2872
17. Shimizu K, Nakata M, Hirami Y et al (2010) Tumor-infiltrating Foxp3? regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected nonsmall cell lung cancer. J Thorac Oncol 5:585-590
18. Ishibashi Y, Tanaka S, Tajima K et al (2006) Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep 15:1315-1319
19. Demaria S, Volm MD, Shapiro RL et al (2001) Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7:3025-3030
20. Halama N, Michel S, Kloor M et al (2009) The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun 9:1-6
21. Halama N, Michel S, Kloor M et al (2011) Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71:5670-5677
22. de Kruijf EM, van Nes JG, Sajet A et al (2010) The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16:1272-1280
23. Ladoire S, Mignot G, Dabakuyo S et al (2011) In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 224:389-400
24. Bosmuller H, Haitchi-Petnehazy S, Webersinke G et al (2011) Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum- based therapy. Virchows Arch 459:183-191
25. Nagai H, Miyaki D, Matsui T et al (2008) Th1/Th2 balance: an important indicator of efficacy for intra-Arterial chemotherapy. Cancer Chemother Pharmacol 62:959-963
26. Bamias A, Tsiatas ML, Kafantari E et al (2007) Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3? CD56? cells with platinum resistance. Gynecol Oncol 106:75-81
27. Suzuki H, Chikazawa N, Tasaka T et al (2010) Intratumoral CD8(?) T/FOXP3 (?) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol Immunother 59:653-661
28. Ohkura N, Hamaguchi M, Sakaguchi S et al (2011) FOXP3? regulatory T cells: control of FOXP3 expression by pharmacological agents. Trends Pharmacol Sci 32:158-166
29. Andersen MH, Sørensen RB, Schrama D et al (2008) Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother 57:1735-1743
30. Denkert C, Loibl S, Noske A et al (2010) Tumor-Associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105-113